2020
Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival
Heller DR, Nicolson NG, Ahuja N, Khan S, Kunstman JW. Association of Treatment Inequity and Ancestry With Pancreatic Ductal Adenocarcinoma Survival. JAMA Surgery 2020, 155: e195047. PMID: 31800002, PMCID: PMC6902102, DOI: 10.1001/jamasurg.2019.5047.Peer-Reviewed Original ResearchConceptsPancreatic ductal adenocarcinomaNational Cancer DatabaseWhite patientsBlack patientsAdvanced diseaseOverall survivalClinical parametersDisease stageCancer DatabaseSurgical proceduresMultivariable Cox proportional hazards regression modelingTreatment inequitiesCox proportional hazards regression modelingPancreatic ductal adenocarcinoma (PDAC) survivalUnadjusted median overall survivalYounger ageProportional hazards regression modelingMedian overall survivalModest survival advantageStage II diseaseNew cancer diagnosesLess chemotherapyResectable cancerCohort studyPrimary outcome
2017
Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer.
Kole AJ, Stahl JM, Park HS, Khan SA, Johung KL. Predictors of Nonadherence to NCCN Guideline Recommendations for the Management of Stage I Anal Canal Cancer. Journal Of The National Comprehensive Cancer Network 2017, 15: 355-362. PMID: 28275036, DOI: 10.6004/jnccn.2017.0035.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntineoplastic Combined Chemotherapy ProtocolsAnus NeoplasmsCombined Modality TherapyDatabases, FactualDisease ManagementFemaleHumansMaleMedication AdherenceMiddle AgedNeoplasm GradingNeoplasm StagingOdds RatioPractice Guidelines as TopicPrognosisProportional Hazards ModelsRisk FactorsTreatment OutcomeConceptsAnal canal cancerAnal cancerNCCN recommendationsSurgical proceduresNCCN Clinical Practice GuidelinesNational Cancer Data BaseGuideline-discordant careAnal canal carcinomaPredictors of nonadherenceClinical practice guidelinesHigh tumor gradeLow-grade tumorsLogistic regression modelingNon-academic facilitiesChi-square testDefinitive chemoradiotherapyGuideline concordantConcurrent chemoradiotherapyAnal carcinomaStandard therapyClinicopathologic factorsGuideline recommendationsMultivariable analysisMale sexTumor size